Literature DB >> 30045852

In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission.

Emma C de Moel1, Veerle F A M Derksen1, Leendert A Trouw1, Holger Bang2, Yvonne P M Goekoop-Ruiterman3, Gerda M Steup-Beekman1,4, Tom W J Huizinga1, Cornelia F Allaart1, René E M Toes1, Diane van der Woude1.   

Abstract

Keywords:  anti-CCP; autoantibodies; rheumatoid arthritis; rheumatoid factor

Mesh：

Substances：

Year:  2018        PMID： 30045852     DOI： 10.1136/annrheumdis-2018-213823

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.

Authors:  Debbie M Boeters; Leonie E Burgers; René Em Toes; Annette van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2019-08-14       Impact factor: 19.103

Review 2.  Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission.

Authors:  Mariola Kurowska-Stolarska; Stefano Alivernini
Journal:  Nat Rev Rheumatol       Date:  2022-06-07       Impact factor: 32.286

Review 3.  From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Diane van der Woude; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2022-05-23       Impact factor: 32.286

Review 4.  Age-associated B cells in autoimmune diseases.

Authors:  Isobel C Mouat; Erin Goldberg; Marc S Horwitz
Journal:  Cell Mol Life Sci       Date:  2022-07-07       Impact factor: 9.207

Review 5.  Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology.

Authors:  Mikhail Volkov; Karin Anna van Schie; Diane van der Woude
Journal:  Immunol Rev       Date:  2019-12-16       Impact factor: 12.988

Review 6.  B cell depletion therapies in autoimmune disease: advances and mechanistic insights.

Authors:  Dennis S W Lee; Olga L Rojas; Jennifer L Gommerman
Journal:  Nat Rev Drug Discov       Date:  2020-12-15       Impact factor: 84.694

7.  The number of risk factors for persistent disease determines the clinical course of early arthritis.

Authors:  N Luurssen-Masurel; A E A M Weel; G H Koc; J M W Hazes; P H P de Jong
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

8.  Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications.

Authors:  M Volkov; A S B Kampstra; K A van Schie; A Kawakami; M Tamai; S Kawashiri; T Maeda; T W J Huizinga; R E M Toes; D van der Woude
Journal:  Arthritis Res Ther       Date:  2021-12-08       Impact factor: 5.156
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.